XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.05% | -34.51% | |||
| Depreciation & Amortization | 0.77% | -21.52% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.16% | -35.08% | |||
| Operating Income | 25.16% | 35.08% | |||
| Income Before Tax | 120.87% | -445.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 120.87% | -445.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 120.87% | -445.09% | |||
| EBIT | 25.16% | 35.08% | |||
| EBITDA | -36.22% | 32.74% | |||
| EPS Basic | 118.50% | -445.05% | |||
| Normalized Basic EPS | 118.51% | -445.36% | |||
| EPS Diluted | 118.45% | -445.05% | |||
| Normalized Diluted EPS | 118.51% | -445.36% | |||
| Average Basic Shares Outstanding | 12.82% | 0.00% | |||
| Average Diluted Shares Outstanding | 12.82% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
